ESTRO 2024 - Abstract Book

S1899

Clinical - Mixed sites, palliation

ESTRO 2024

Induced Oligorecurrence 6 (4.0%) Induced Oligopersistance 10 (6.7%) Induce Oligoprogression 46 (30.6%)

* ESTRO/EORTC consensus on oligometastases classification1

Conclusion:

Stereotactic treatment for liver metastases seems to be a safe and promising option in terms of LC. Moreover, at least 50% of the patients remained free from the start of a new systemic line at one-year post-treatment.

Keywords: SBRT, liver, oligometastases

References:

1. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Méndez Romero A, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020 Jan;21(1):e18-e28. doi: 10.1016/S1470-2045(19)30718-1. PMID: 31908301.

1164

Digital Poster

Abscopal effects in patients with radiotherapy and checkpoint inhibition: a study of the young DEGRO

Simone Wegen 1,2 , Alexander Rühle 3 , Allison Lamrani 4 , Charlotte Schmitter 4 , Justus Kaufmann 5 , Matthias Mäurer 6,7 , Georg Wurschi 6,8 , Ping Jiang 9 , Felix Ehret 10 , Andrea Baehr 11 , Annika Hardt 12 , Raphael Bodensohn 13,14 , Lukas Käsmann 13 , Maria Waltenberger 15,16,17 , Julian P. Layer 18,19 , Davide Scafa 18 , Danny Jazmati 20 , Sebastian Neppl 1 , Anna Hagemeier 21 , Maike Trommer 1,22,23 1 Faculty of Medicine and University Hospital Cologne, Department of Radiation Oncology, Cyberknife and Radiotherapy, Cologne, Germany. 2 Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, CIO, Cologne, Germany. 3 Medical Center, Faculty of Medicine, University of Freiburg, Department of Radiation Oncology, Freiburg, Germany. 4 University Hospital Erlangen, Department of Radiation Oncology, Erlangen, Germany. 5 University Medical Center of the Johannes Gutenberg University, Department of Radiation Oncology, Mainz, Germany. 6 University Hospital Jena, Department of Radiation Oncology, Jena, Germany. 7 University Hospital Jena, Clinician Scientist Program OrganAge, Jena, Germany. 8 University Hospital Jena, Clinician Scientist Program, IZKF, Jena, Germany. 9 Pius Hospital Oldenburg, University Medicine Oldenburg, Department of Radiation Oncology and Radiotherapy, Oldenburg, Germany. 10 Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and